Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1

被引：0
|
作者：
Jamaal L. James
Justin M. Balko
机构：
[1] Vanderbilt University Medical Center,Department of Medicine
[2] Vanderbilt University Medical Center,Cancer Biology Program
[3] Vanderbilt University Medical Center,Department of Pathology, Microbiology and Immunology
[4] Vanderbilt University Medical Center,Breast Cancer Research Program
来源：
Current Breast Cancer Reports | 2019年 / 11卷
关键词：
Breast cancer; Biomarkers; Programmed death-ligand 1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：217 / 227
页数：10
相关论文
共 50 条
  • [31] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [32] Is PD-L1 Expression a Biomarker of Response?
    不详
    CANCER DISCOVERY, 2015, 5 (12) : 1232 - 1232
  • [33] PD-L1 in Breast Cancer: The Road to the Perfect Biomarker Is Fraught With Uncertainty
    Lim, Bora
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (08): : 951 - 952
  • [34] Systemic CD4 immunity: A powerful clinical biomarker for PD-L1/PD-1 immunotherapy
    Zuazo, Miren
    Arasanz, Hugo
    Bocanegra, Ana
    Chocarro, Luisa
    Vera, Ruth
    Escors, David
    Kagamu, Hiroshi
    Kochan, Grazyna
    EMBO MOLECULAR MEDICINE, 2020, 12 (09)
  • [35] PD-1/PD-L1 and immunotherapy for pancreatic cancer
    Feng, Mengyu
    Xiong, Guangbing
    Cao, Zhe
    Yang, Gang
    Zheng, Suli
    Song, Xujun
    You, Lei
    Zheng, Lianfang
    Zhang, Taiping
    Zhao, Yupei
    CANCER LETTERS, 2017, 407 : 57 - 65
  • [36] Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors.
    Khunger, Monica
    Rakshit, Sagar
    Schalper, Kurt Alex
    Elson, Paul
    Pennell, Nathan A.
    Stevenson, James
    Velcheti, Vamsidhar
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis
    Tabana, Yasser
    Okoye, Isobel S.
    Siraki, Arno
    Elahi, Shokrollah
    Barakat, Khaled H.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [38] Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1
    Guo, Jiazheng
    Yu, Fengyi
    Zhang, Kuojun
    Jiang, Sheng
    Zhang, Xiangyu
    Wang, Tianyu
    RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1096 - 1108
  • [39] An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response
    Didem Naz Dioken
    Ibrahim Ozgul
    Irem Yilmazbilek
    Mustafa Cengiz Yakicier
    Ezgi Karaca
    Ayse Elif Erson-Bensan
    Cancer Immunology, Immunotherapy, 2023, 72 : 4065 - 4075
  • [40] PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
    Bocanegra, Ana
    Blanco, Ester
    Fernandez-Hinojal, Gonzalo
    Arasanz, Hugo
    Chocarro, Luisa
    Zuazo, Miren
    Morente, Pilar
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) : 1 - 17
12345